Expected increases in life expectancy together with increasingly complex physical and mental illness will continue to exert huge pressures on health systems. How should the UK prepare for the challenges ahead?
The nation's public umbilical cord blood banks provide benefits that far outweigh their costs and should continue to receive federal support, even though use of cord blood stem cells from the banks has been declining.
U.S. umbilical cord blood banks are a valuable resource for patients and the research community. Their benefits far outweigh their costs, and they should continue to receive federal support. There are strategies available to strengthen public cord banks and broaden their usefulness.
RAND studied trends affecting public cord blood banks and considered changes to the program to buttress banks' financial stability. Researchers found a system worthy of investment, especially if it helps improve the quality of the national inventory.
The report presents findings from a survey conducted by RAND Europe at the request of the National Institute for Health Research to gather and synthesise stakeholder views on the future of health and healthcare in England in 20 to 30 years' time.
The Office of Health Economics and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This programme of research has looked at the health, economic and scientific impact of Oxford BRC's research activity.
Publicly funded biomedical and health research is expected to achieve the best return possible for taxpayers and for society generally. It is therefore important to know whether such research is more productive if concentrated into a small number of 'research groups' or dispersed across many.
Biomedical research can have impacts on patient care at research-active hospitals. We qualitatively evaluated the impact of the Oxford Biomedical Research Centre (Oxford BRC), a university-hospital partnership, on the effectiveness and efficiency of healthcare in local hospitals.
This report presents a bibliometric analysis of biomedical and health research in England, 2004-2013. It is intended to support the shortlisting and selection of the National Institute for Health Research Biomedical Research Centres in England.
The time taken, or 'time lags', between biomedical/health research and its translation into health improvements is receiving growing attention. Reducing time lags should increase rates of return to such research.
To make an impact on patient care within a 20-year timeframe, biomedical research funders and policymakers should focus resources on clinical rather than basic research, and support individuals who work across disciplinary boundaries and are motivated by patient need.
This paper highlights key points from a high-level Forum organised and facilitated by the Office of Health Economics and RAND Europe that discussed spillover effects from biomedical and health research, and strategies to realise their benefits.
Describes a review of the NIHR Biomedical Research Units scheme. This review was a perceptions audit of senior executives involved in the scheme, and explored what impact they felt the scheme is having on the translational research landscape.
The report is a review of the BRC scheme. It examines the scheme’s impacts on changes in institutional relationships between the NHS, academia, industry; capacity-building in the health research system, resource-targeting, management and governance.